Abstract
The pathophysiology of hyperglycemia in type 2 diabetes (T2DM) involves 3 main defects: insulin deficiency, excess hepatic glucose output, and insulin resistance. Oral anti-diabetic agents act in a variety of ways. These include agents that stimulate insulin secretion, reduce hepatic glucose production, delay digestion and absorption of intestinal carbohydrate or improve insulin action. Because of improved knowledge of pathophysiology, new drugs with mechanisms of action focussed on specific pathophysiological alterations have appeared, in order to utilize all the possibilities of treating this condition. Here, we focus on the new agents used in the latest years and the overcoming ones in future, in particular incretin-based therapies, drugs inhibiting kidney glucose reabsorption (SGLT2 inhibitors), and glucokinase activators. The strategy for new drug development advocated here is to establish a broad range of anti-diabetic medicines with different mechanisms of action and potential opportunities for effective combination therapies.
Similar content being viewed by others
References
Krentz AJ, Bailey CJ (2005) Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 65:385–411
Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA (2001) Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24:710–719
Tan MH, Baksi A, Krahulec B, Kubalski P, Stankiewicz A, Urquhart R, Edwards G, Johns D, The GLAL Study Group (2005) Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care 28:544–550
Durbin RJ (2004) Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab 6:280–285
Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP (2002) Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51:2796–2803
Matsui J, Terauchi Y, Kubota N, Takamoto I, Eto K, Yamashita T, Komeda K, Yamauchi T, Kamon J, Kita S, Noda M, Kadowaki T (2004) Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-γ-deficient mice on a high-fat diet. Diabetes 53:2844–2854
Kendall DM (2006) Thiazolidinediones the case for early use. Diabetes Care 29:154–157
Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB (2010) Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 33:428–433
Klonoff DC, Buse JB, Nielsen LL et al (2008) Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 24:275–286
Trujillo J (2006) Incretin hormones in the treatment of type 2 diabetes. Formulary 41:130–141
Hansotia T, Baggio LL, Delmeire D, Hinke SA, Yamada Y, Tsukiyama K, Seino Y, Holst JJ, Schuit F, Drucker DJ (2004) Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53:1326–1335
Wright EM, Hirayama BA, Loo DF (2007) Active sugar transport in health and disease. J Intern Med 261:32–43
Rahmoune H, Thomson PW, Ward JM (2005) Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54:3427–3434
Bays H (2009) From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin 25:671–681
Chao EC (2011) A paradigm shift in diabetes therapy–dapagliflozin and other SGT2 inhibitors. Discov Med 11:255–263
Bedoya FJ, Matschinsky FM, Shimizu T, O’Neil JJ, Appel MC (1986) Differential regulation of glucokinase activity in pancreatic islets and liver of the rat. J Biol Chem 261:10760–10764
Grimsbt J, Sarabu R, Corbett WL et al (2003) Allosteric activators of glucokinase: potential role in diabetes therapy. Science 301:370–373
Leighton B, Atkinson A, Coghlan MP (2005) Small molecule glucokinase activators as novel anti-diabetic agents. Biochem Soc Trans 33:371–374
Matschinsky FM (2009) Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 8:399–416
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cavallo Perin, P., Fornengo, P. New oral antidiabetic agents. Intern Emerg Med 6 (Suppl 1), 135 (2011). https://doi.org/10.1007/s11739-011-0677-5
Published:
DOI: https://doi.org/10.1007/s11739-011-0677-5